IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4020
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$35M
Eric Easom
AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ANTX AN2 Therapeutics, Inc. | 36 | 26 | 8 | 42 | - | - | -64.9% | -58.3% | - | - | - | - | 0.0% | 11.0x | $35M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
AN2 Therapeutics, Inc. (ANTX) receives a "Avoid" rating with a composite score of 35.9/100. It ranks #4020 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ANTX.
View All RatingsROE proxy -64.9% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate AN2 Therapeutics, Inc. (ANTX) as Avoid with a composite score of 35.9/100 at a current price of $1.05. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
AN2 Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.9/100 places it at rank #4020 in our full universe.
No Moat
Low
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
AN2 Therapeutics, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags AN2 Therapeutics, Inc. with an Avoid rating, assigning a composite score of 35.9/100 and 1 out of 5 stars. Ranked #4020 of 7,333 stocks, ANTX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ANTX's quality score of 26/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -64.9% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
ANTX registers a value score of just 8/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.47x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
AN2 Therapeutics, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -58.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ANTX is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.62 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ANTX shows good financial stability with a score of 71/100. Key stability metrics include a beta of 0.62 and a debt-to-equity ratio of 11.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
ANTX carries a short interest score of 63/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 11.00x), micro-cap liquidity risk. At $35M market cap (micro-cap), AN2 Therapeutics, Inc. offers reasonable institutional liquidity.
AN2 Therapeutics, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4020 of 7,333 overall (45th percentile). Key comparisons include ROE of -64.9% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ANTX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (8) would have the largest impact on the composite score.
ROE 3318% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 5138% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
MENLO PARK, Calif., February 17, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET.
MENLO PARK, Calif., January 12, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration has cleared Oregon Health & Science University’s (OHSU) Investigational New Drug (IND) application to proceed with an IIT that will evaluate the safety, efficacy, and pharmacokinetics of epetraborole in patients with Mycobacterium abscessus lung dis
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ: MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.com shares dipped 10.1% to close at $212.01 on Monday. See how other analysts view this stock. Needham cut G1 Therapeutics, Inc. (NASDAQ: GTHX) price target from $14 to $12. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 1.1% to close at $4.48 on Monday. See how other analysts view this stock. Needham boosted the price target for Cadence Design Systems, Inc. (NASDAQ: CDNS) from $315 to $320. Needham analyst Charles Shi maintained a Buy rating. Cadence Design shares fell 1.7% to close at $306.58 on Monday. See how other analysts view this stock. B. Riley Securities cut The Children's Place, Inc. (NASDAQ:
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ: MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated video modernization with NVIDIA at the ACM Mile-High-Video 2024 conference. DIH Holdings US, Inc. (NASDAQ: DHAI) shares climbed 65.2% to $2.1306. DIH Holding US secured $1.5 million in private placement financing from OrbiMed. ContextLogic Inc. (NASDAQ: WISH) gained 40.2% to $6.31 after the company announced an agreement to sell substantially all of its operating assets and liabilities to Qoo10 for approximately $173 million in cash. SuperCom Ltd. (NASDAQ: SPCB) shares jumped 40% to $0.2570. SuperCom recently disclosed that it has secured a new contract with an established California services provider in the judicial sector. Intuitive Machines, Inc. (NASDAQ: LUNR) shares gained 33.3% to $6.65 after jumping around 32% on Friday. D-Wave Quantum Inc. (NYSE: QBTS) gained 31% to $1.4295. Renalytix Plc (NASDAQ: RNLX) surged 27% to $0.4842. Genasys Inc. (NASDAQ: GNSS) gained 27% to $1.98. Genasys bagged critical infrastructure project to engineer, procure and build emergency warning system for 37 dams across the island of Puerto Rico. Root, Inc. (NASDAQ: ROOT) rose 22.6% to $9.30. Syra Health Corp. (NASDAQ: SYRA) ...
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500 also rose, gaining, 0.30% to 5,041.87. Check This Out: Caterpillar, Marathon Petroleum And More On CNBC's 'Final Trades' Leading and Lagging Sectors Energy shares rose by 1.1% on Monday. In trading on Monday, health care shares fell by 0.1%. Top Headline Gilead Sciences Inc (NASDAQ: GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio. Equities Trading UP Beamr Imaging Ltd. (NASDAQ: BMR) shares shot up 975% to $22.70 after the company announced it will present its joint ...